Speciated High-Density Lipoprotein Biogenesis and Functionality
- PMID: 27005803
- DOI: 10.1007/s11883-016-0572-7
Speciated High-Density Lipoprotein Biogenesis and Functionality
Abstract
Plasma high-density lipoprotein cholesterol (HDL-C) concentration is a negative risk factor for atherosclerotic cardiovascular disease (CVD). Despite this, most attempts to raise plasma HDL-C concentrations in a cardioprotective way have failed. Recently, hypotheses about the atheroprotective effects of HDL have shifted away from quantity to quality, mostly HDL function in reverse cholesterol transport. Plasma HDL from CVD patients is a poorer acceptor of cellular cholesterol than plasma from healthy controls, independent of plasma HDL-C concentrations. The function of HDL is likely determined by two other factors, stability and composition. The kinetic instability of HDL, which varies according to subclass, is a likely determinant of its reactivity in response to many HDL-modifying activities. HDL composition is also heterogeneous and variable; all HDL particles contain apo AI but only about two-thirds contain apo AII. This occurs despite the fact that apo AI and apo AII are hepatically secreted on separate HDL that later fuse in plasma. HDL also contains traces of other proteins, some of which have not yet been associated with HDL function. One minor HDL species are those that are secreted with intact signal peptides, which enhances their binding to HDL; these HDL have special properties that are independent of cholesterol transport. Here, we review and provide a perspective about what is currently known about speciated HDL biogenesis in the context of health and disease.
Keywords: Apolipoproteins; Atherosclerosis; Cholesterol; HDL; Signal peptide.
Similar articles
-
Novel Approaches for HDL-Directed Therapies.Curr Atheroscler Rep. 2017 Nov 4;19(12):55. doi: 10.1007/s11883-017-0699-1. Curr Atheroscler Rep. 2017. PMID: 29103206 Review.
-
Apolipoprotein A-II is a key regulatory factor of HDL metabolism as appears from studies with transgenic animals and clinical outcomes.Biochimie. 2014 Jan;96:56-66. doi: 10.1016/j.biochi.2013.08.027. Epub 2013 Sep 5. Biochimie. 2014. PMID: 24012775 Review.
-
Characterization of apolipoprotein A-I- and A-II-containing lipoproteins in a new case of high density lipoprotein deficiency resembling Tangier disease and their effects on intracellular cholesterol efflux.J Clin Invest. 1993 Feb;91(2):522-9. doi: 10.1172/JCI116231. J Clin Invest. 1993. PMID: 8432861 Free PMC article.
-
Familial apolipoprotein AI and apolipoprotein CIII deficiency. Subclass distribution, composition, and morphology of lipoproteins in a disorder associated with premature atherosclerosis.J Clin Invest. 1984 Nov;74(5):1601-13. doi: 10.1172/JCI111576. J Clin Invest. 1984. PMID: 6501564 Free PMC article.
-
Association of cholesterol concentrations in low-density lipoprotein, high-density lipoprotein, and high-density lipoprotein subfractions, and of apolipoproteins AI and AII, with coronary stenosis and left ventricular function.J Lab Clin Med. 1987 Jan;109(1):19-26. J Lab Clin Med. 1987. PMID: 3098880
Cited by
-
Inverse Correlation of Cholesterol Efflux Capacity with Peripheral Plaque Volume Measured by 3D Ultrasound.Biomedicines. 2023 Jul 6;11(7):1918. doi: 10.3390/biomedicines11071918. Biomedicines. 2023. PMID: 37509557 Free PMC article.
-
Efficacy and Safety of Low-Dose Pemafibrate Therapy for Hypertriglyceridemia in Patients with Type 2 Diabetes.JMA J. 2021 Apr 15;4(2):135-140. doi: 10.31662/jmaj.2020-0104. Epub 2021 Mar 26. JMA J. 2021. PMID: 33997447 Free PMC article.
-
Current and Emerging Reconstituted HDL-apoA-I and HDL-apoE Approaches to Treat Atherosclerosis.J Pers Med. 2018 Oct 3;8(4):34. doi: 10.3390/jpm8040034. J Pers Med. 2018. PMID: 30282955 Free PMC article. Review.
-
Effects of Disease-Causing Mutations on the Conformation of Human Apolipoprotein A-I in Model Lipoproteins.Biochemistry. 2018 Jul 31;57(30):4583-4596. doi: 10.1021/acs.biochem.8b00538. Epub 2018 Jul 13. Biochemistry. 2018. PMID: 30004693 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources